| Co-Investigator(Kenkyū-buntansha) |
KODERA Yasuhiro 名古屋大学, 医学系研究科, 教授 (10345879)
UCHIDA Hiroaki 東京大学, 医科学研究所, 講師 (20401250)
YAMADA Suguru 名古屋大学, 医学部附属病院, 病院講師 (30467287)
SHIKU Hiroshi 三重大学, 医学系研究科, 産学連携講座教員 (80154194)
NOMOTO Shuji 名古屋大学, 医学部附属病院, 病院講師 (40300967)
|
|---|
| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we investigated the possibility of systemic administration of HF10 adsorbed on the tumor antigen-specific lymphocytes. We administered adsorbed HF10 to the tail vein of mice with subcutaneous tumor expressed ovalbumin antigen and analyzed the efficacy of this treatment. HF10 absorbed on ovalbumin antigen-specific T cells showed significant antitumor effect more than control group. Our results suggest that HF10 adsorbed on tumor antigen-specific lymphocytes could be delivered systemically without interference of host immune response, and it have significant potential in treatment of the disseminated tumors. We acquired precious basic data for clinical trial.
|
